Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 132

1.

Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.

Soriano G, Heaney M.

Curr Opin Hematol. 2013 Mar;20(2):169-75. doi: 10.1097/MOH.0b013e32835d82fe. Review.

PMID:
23298878
2.

Myeloproliferative neoplasms: Current molecular biology and genetics.

Saeidi K.

Crit Rev Oncol Hematol. 2016 Feb;98:375-89. doi: 10.1016/j.critrevonc.2015.11.004. Epub 2015 Nov 28. Review.

PMID:
26697989
3.
4.

JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.

Kilpivaara O, Levine RL.

Leukemia. 2008 Oct;22(10):1813-7. doi: 10.1038/leu.2008.229. Epub 2008 Aug 28. Review.

PMID:
18754026
5.

Mutations profile of polycythemia vera and essential thrombocythemia among Japanese children.

Ismael O, Shimada A, Hama A, Sakaguchi H, Doisaki S, Muramatsu H, Yoshida N, Ito M, Takahashi Y, Akita N, Sunami S, Ohtsuka Y, Asada Y, Fujisaki H, Kojima S.

Pediatr Blood Cancer. 2012 Sep;59(3):530-5. doi: 10.1002/pbc.23409. Epub 2011 Nov 21.

PMID:
22106054
6.

JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms.

Oh ST, Gotlib J.

Expert Rev Hematol. 2010 Jun;3(3):323-37. doi: 10.1586/ehm.10.28. Review.

PMID:
21082983
7.

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.

Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR.

Haematologica. 2011 Oct;96(10):1462-9. doi: 10.3324/haematol.2011.045591. Epub 2011 Jun 28.

8.

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

Tefferi A, Lasho TL, Abdel-Wahab O, Guglielmelli P, Patel J, Caramazza D, Pieri L, Finke CM, Kilpivaara O, Wadleigh M, Mai M, McClure RF, Gilliland DG, Levine RL, Pardanani A, Vannucchi AM.

Leukemia. 2010 Jul;24(7):1302-9. doi: 10.1038/leu.2010.113. Epub 2010 May 27.

9.

Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a.

Quintás-Cardama A, Abdel-Wahab O, Manshouri T, Kilpivaara O, Cortes J, Roupie AL, Zhang SJ, Harris D, Estrov Z, Kantarjian H, Levine RL, Verstovsek S.

Blood. 2013 Aug 8;122(6):893-901. doi: 10.1182/blood-2012-07-442012. Epub 2013 Jun 19.

10.

Clonal analyses reveal associations of JAK2V617F homozygosity with hematologic features, age and gender in polycythemia vera and essential thrombocythemia.

Godfrey AL, Chen E, Pagano F, Silber Y, Campbell PJ, Green AR.

Haematologica. 2013 May;98(5):718-21. doi: 10.3324/haematol.2012.079129.

11.

Different involvement of the megakaryocytic lineage by the JAK2 V617F mutation in Polycythemia vera, essential thrombocythemia and chronic idiopathic myelofibrosis.

Hussein K, Brakensiek K, Buesche G, Buhr T, Wiese B, Kreipe H, Bock O.

Ann Hematol. 2007 Apr;86(4):245-53. Epub 2007 Jan 30.

PMID:
17262192
12.

Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.

Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD, Duval A, Maynadié M, Hermouet S.

Haematologica. 2008 Nov;93(11):1723-7. doi: 10.3324/haematol.13081. Epub 2008 Aug 25. Erratum in: Haematologica. 2010 Feb;95(2):344. Vidal, Aurélie [corrected to Duval, Aurélie].

13.
14.

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.

Tefferi A, Vainchenker W.

J Clin Oncol. 2011 Feb 10;29(5):573-82. doi: 10.1200/JCO.2010.29.8711. Epub 2011 Jan 10. Review.

PMID:
21220604
15.

JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.

Panova-Noeva M, Marchetti M, Buoro S, Russo L, Leuzzi A, Finazzi G, Rambaldi A, Ottomano C, Ten Cate H, Falanga A.

Blood. 2011 Sep 1;118(9):2599-601. doi: 10.1182/blood-2011-02-339655. Epub 2011 Jul 12.

16.

Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.

Tibes R, Bogenberger JM, Benson KL, Mesa RA.

Mol Diagn Ther. 2012 Oct;16(5):269-83. doi: 10.1007/s40291-012-0006-3. Review.

PMID:
23023734
17.

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal.

Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A.

Leukemia. 2008 Jul;22(7):1299-307. doi: 10.1038/leu.2008.113. Epub 2008 May 22. Review.

PMID:
18496562
18.
19.

Myeloproliferative neoplasms: A decade of discoveries and treatment advances.

Tefferi A.

Am J Hematol. 2016 Jan;91(1):50-8. doi: 10.1002/ajh.24221. Review.

20.

JAK2V617F-negative ET patients do not display constitutively active JAK/STAT signaling.

Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL.

Exp Hematol. 2007 Nov;35(11):1695-703. Epub 2007 Aug 30.

Supplemental Content

Support Center